Maze Therapeutics (MAZE) is scheduled to report Q1 earnings on May 13, 2026. Analysts estimate EPS of $-0.55 and quarterly revenue of $11.60M.

In the most recent quarter (Q4), Maze Therapeutics reported EPS of $-0.65, beating estimates of $-0.71 by 0.08%. Revenue came in at $0.00, meeting the estimate of $0.00 by 0.00%.

Maze Therapeutics has beaten EPS estimates in 3 consecutive quarters.

Over the last 3 quarters, Maze Therapeutics has averaged an EPS surprise of 0.11% and a revenue surprise of 1.00%.